Neurons expressing GPR3 (G protein-coupled receptor 3), also known as Gs-coupled receptor 3, represent a population of neurons with unique signaling properties due to the constitutive activity of the GPR3 receptor[@thathiah2009]. GPR3 is a member of the rhodopsin family of G protein-coupled receptors (GPCRs) and is characterized by its ability to activate Gs proteins even in the absence of a known ligand, making it a constitutively active receptor with significant implications for neuronal signaling and neurodegenerative diseases[@uhlen2005].
Introduction
GPR3 is an orphan G-protein-coupled receptor that is predominantly expressed in neurons throughout the central nervous system, with particularly high expression in the cerebral cortex, hippocampus, and cerebellum[@cao2016]. Unlike most GPCRs that require ligand binding for activation, GPR3 exhibits constitutive (ligand-independent) activity, continuously activating Gs signaling pathways and elevating intracellular cAMP levels. This unique property has made GPR3 an interesting target for research into neurodegenerative diseases, particularly Alzheimer's disease, where it has been shown to influence amyloid precursor protein (APP) processing and amyloid-beta (Aβ) production[@thathiah2013].
Neurons expressing GPR3 (G protein-coupled receptor 3), also known as Gs-coupled receptor 3, represent a population of neurons with unique signaling properties due to the constitutive activity of the GPR3 receptor[@thathiah2009]. GPR3 is a member of the rhodopsin family of G protein-coupled receptors (GPCRs) and is characterized by its ability to activate Gs proteins even in the absence of a known ligand, making it a constitutively active receptor with significant implications for neuronal signaling and neurodegenerative diseases[@uhlen2005].
Introduction
GPR3 is an orphan G-protein-coupled receptor that is predominantly expressed in neurons throughout the central nervous system, with particularly high expression in the cerebral cortex, hippocampus, and cerebellum[@cao2016]. Unlike most GPCRs that require ligand binding for activation, GPR3 exhibits constitutive (ligand-independent) activity, continuously activating Gs signaling pathways and elevating intracellular cAMP levels. This unique property has made GPR3 an interesting target for research into neurodegenerative diseases, particularly Alzheimer's disease, where it has been shown to influence amyloid precursor protein (APP) processing and amyloid-beta (Aβ) production[@thathiah2013].
Location and Distribution
GPR3-expressing neurons are found in several brain regions:
Cerebral Cortex
Layer 2/3 pyramidal neurons
Layer 5 corticostriatal neurons
Interneurons in cortical circuits
Hippocampus
CA1 pyramidal neurons
Dentate gyrus granule cells
Hippocampal interneurons
Cerebellum
Purkinje cells
Cerebellar granule cells
Deep cerebellar nuclei neurons
Other Regions
Substantia nigra pars compacta
[Striatum](/brain-regions/striatum)
[Thalamus](/brain-regions/thalamus)
Function
GPR3 neurons are characterized by several key functional properties[@huang2015]:
Constitutive Gs Signaling
Continuous activation of Gs proteins
Elevated baseline cAMP levels
Protein kinase A (PKA) activation
CREB phosphorylation and gene transcription
Amyloid Precursor Protein Processing
GPR3 activity increases amyloidogenic processing of APP
Enhances β-secretase (BACE1) activity
Promotes amyloid-beta generation
Genetic variants associated with AD risk
Synaptic Transmission Modulation
Regulation of neurotransmitter release
Modulation of synaptic vesicle cycling
Influence on long-term potentiation (LTP)
Effects on synaptic plasticity
Neuronal Survival
cAMP-dependent pro-survival signaling
Regulation of autophagy
Mitochondrial function modulation
Role in Disease
Alzheimer's Disease
GPR3 has emerged as a significant factor in Alzheimer's disease pathogenesis[@liu2020]:
Amyloid Production: GPR3 activity directly increases amyloid-beta production by promoting the amyloidogenic pathway of APP processing
Genetic Association: Single nucleotide polymorphisms (SNPs) in the GPR3 gene have been associated with increased AD risk in genome-wide association studies (GWAS)
Therapeutic Target: GPR3 antagonists may reduce amyloid production and represent a potential therapeutic strategy for AD
Expression Changes: Altered GPR3 expression observed in AD brain tissue
Parkinson's Disease
GPR3 expressed in dopaminergic neurons of substantia nigra
The study of Gpr3 Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data